Depratal 30mg 28 tablets — Made in Poland by Adamed — Free Delivery

active substance: duloxetine hydrochloride;

1 enteric tablet contains duloxetine hydrochloride, which is equivalent to duloxetine 30 mg;

auxiliary substances: pressed sugar, corn starch, magnesium stearate;

shell composition: methacrylic acid-ethyl acrylate copolymer (1:1), dispersion 30%; triethyl citrate; talc; titanium dioxide (E 171); simethicone emulsion.

Symptoms. There have been cases of overdose when using duloxetine 5400 mg as monotherapy or in combination with other preparations. A few deaths have been reported primarily in mixed overdose, but there have also been deaths following duloxetine alone at a dose of approximately 1000 mg. Signs and symptoms of overdose (duloxetine alone or in combination with other preparations) included drowsiness, coma, serotonin syndrome, convulsions, vomiting, and tachycardia. Overdose symptoms (mainly when taken in combination with other preparations) included drowsiness, coma, serotonin syndrome, epileptic seizures, vomiting and tachycardia.

Specific antidotes are not known; when serotonin syndrome occurs, specific treatment (cyproheptadine and/or temperature control) is necessary. Airway patency should be checked. Cardiac monitoring and monitoring of vital signs is recommended, along with appropriate symptomatic and supportive measures. Gastric lavage may be appropriate if it is performed immediately after taking the preparation or for symptomatic purposes. Activated charcoal reduces the absorption of the preparation. Duloxetine has a large volume of distribution in the body, and therefore forced diuresis, hemoperfusion and exchange perfusion are unlikely to be useful.

Contraindication for the use of the preparation is hypersensitivity to duloxetine or to any excipients of the preparation.

Duloxetine should not be administered together with non-selective irreversible MAOIs (MAOIs).

Duloxetine should not be given to patients with unstable hypertension as it may precipitate a hypertensive crisis.

Duloxetine should not be given to patients with end-stage renal disease (creatinine clearance <30 ml/min).

Duloxetine should not be given to patients with liver disease as it may lead to liver failure.

Duloxetine should not be given in combination with fluvoxamine, ciprofloxacin or enoxacin (strong inhibitors of CYP1A2) due to increased plasma concentrations of duloxetine.

Store below 25°C in original packaging.

Keep out of the reach of children.